$BPTH News

Last published 1y ago

1y agoADIA ATNM BPTH CNVIF+12Life Sciences Investor Forum: Now Available for Online ViewingGlobeNewswireNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and
1y agoADIA ATNM BPTH CNVIF+12Life Sciences Investor Forum Agenda Announced for June 11th-12thGlobeNewswireNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is
1y agoBPTHBio-Path Holdings Provides Clinical and Operational UpdateGlobeNewswireHOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
1y agoBPTHBio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025GlobeNewswireHOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
1y agoBPTHBio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes PatientsGlobeNewswireHOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of
1y agoBPTHBio-Path Holdings Reports Full Year 2024 Financial ResultsGlobeNewswireHOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
1y agoBPTHBio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes PatientsGlobeNewswireHOUSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
1y agoBPTHBio-Path Holdings Expands Global Patent PortfolioGlobeNewswireHOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
1y agoBPTHBio-Path Holdings Provides Key Clinical UpdatesGlobeNewswireFirst Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase 2 Triple
1y agoBPTHBio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid LeukemiaGlobeNewswireStudy Progresses to Fourth Higher 90 mg/m2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, 2025 (GLOBE
1y agoBPTHBio-Path Holdings Provides 2025 Clinical and Operational UpdateGlobeNewswireAdvancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc.,
1y agoBPTHBio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin SensitivityGlobeNewswireHOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
1y agoBPTHBio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes PatientsGlobeNewswireExtensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic Program and Discontinues Enrollment in Phase 1 Study of
1y agoBPTHBio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoBPTHBio-Path Holdings Reports Third Quarter 2024 Financial ResultsGlobeNewswireExpands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology
2y agoBPTHBio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024GlobeNewswireHOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
2y agoBPTHBio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireHOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense
2y agoBPTHBio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireHOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense
2y agoBPTHBio-Path Holdings Initiates Development of Therapeutic Program for Treatment of ObesityGlobeNewswireHOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
2y agoBPTHBio-Path Holdings Announces Publication in BiomedicinesGlobeNewswireManuscript Highlights Therapeutic Potential of BP1003 in Variety of Cancers Marks Company's Twenty-Second Peer-Reviewed Publication in Support of its DNAbilize® Technology HOUSTON, Sept. 16, 2024 (GLOBE
2y agoBPTHBio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireHOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
2y agoBPTHBio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid TumorsGlobeNewswireFirst Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase 2 Triple
2y agoBPTHBio-Path Holdings, Inc. (BPTH) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoBPTHBio-Path Holdings Reports Second Quarter 2024 Financial ResultsGlobeNewswireHOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
2y agoBPTHBio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024GlobeNewswireHOUSTON , Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
2y agoBPTHBio-Path Holdings Provides Clinical Update and Expansion PlansGlobeNewswireMarks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE
2y agoATNM BMY BPTH LGVN+1Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials IncreaseGlobeNewswirePALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and
2y agoBPTHBio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association CongressGlobeNewswireHOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
2y agoBPTHBio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireHOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense
2y agoBPTHBio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireHOUSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense
2y agoBPTHBio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireHOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
2y agoBPTHBio-Path Holdings to Present Data at 2024 European Hematology Association CongressGlobeNewswireHOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of
2y agoBPTHBio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireHOUSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of
2y agoBPTHBio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoBPTHBio-Path Holdings Reports First Quarter 2024 Financial ResultsGlobeNewswireMarks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings,
2y agoBPTHBio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024GlobeNewswireHOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
2y agoBPTHBio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireHOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) (the "Company" or "Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
2y agoBPTHBio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireHOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) (the "Company" or "Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
2y agoBPTHBio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) PatientsGlobeNewswireHOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
2y agoBPTHBio-Path Holdings Expands Global Patent PortfolioGlobeNewswireHOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
2y agoBPTHBio-Path Holdings Provides 2024 Clinical and Operational UpdateGlobeNewswireHOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
2y agoBPTHBio-Path Holdings Reports Full Year 2023 Financial ResultsGlobeNewswireHOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
2y agoBPTHBio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024GlobeNewswireHOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
2y agoBPTHBio-Path Holdings Announces 1-for-20 Reverse Stock SplitGlobeNewswireHOUSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (the "Company"), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a
2y agoBPTHBio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia PatientsGlobeNewswireHOUSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
2y agoBPTHBio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid LeukemiaGlobeNewswireHOUSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
2y agoBPTHBio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoBPTHBio-Path Holdings Reports Third Quarter 2023 Financial ResultsGlobeNewswireHOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
3y agoBPTHBio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023GlobeNewswireHOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
3y agoBPTHBio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid LeukemiaGlobeNewswireHOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of